Holen Sie sich die Stockscreener-App
87.56
2.07%
-1.85
Handel nachbörslich:
87.56
Schlusskurs vom Vortag:
$89.41
Offen:
$88.71
24-Stunden-Volumen:
1.41M
Relative Volume:
0.60
Marktkapitalisierung:
$16.94B
Einnahmen:
$8.41B
Nettoeinkommen (Verlust:
$760.80M
KGV:
22.74
EPS:
3.8513
Netto-Cashflow:
$1.05B
1W Leistung:
+4.03%
1M Leistung:
+0.33%
6M Leistung:
-6.93%
1J Leistung:
-6.32%
1-Tages-Spanne:
$87.50
$88.78
1-Wochen-Bereich:
$84.32
$91.84
52-Wochen-Spanne:
$79.12
$108.29
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Firmenname
Zimmer Biomet Holdings Inc
Sektor
Branche
Telefon
(574) 267-6131
Adresse
345 EAST MAIN STREET, WARSAW, IN
Compare ZBH vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZBH
Zimmer Biomet Holdings Inc
|
87.56 | 17.30B | 8.41B | 760.80M | 1.05B | 3.8513 |
ABT
Abbott Laboratories
|
95.18 | 166.94B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
326.85 | 126.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
82.01 | 107.31B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.81 | 67.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
93.64 | 54.60B | 6.30B | 1.07B | 1.09B | 1.8406 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-23 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-02-20 | Eingeleitet | William Blair | Mkt Perform |
| 2026-01-09 | Herabstufung | Goldman | Neutral → Sell |
| 2026-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2026-01-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-12-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-11-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-09-18 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-07-15 | Hochstufung | Roth Capital | Neutral → Buy |
| 2024-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-10 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-07-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-21 | Hochstufung | Argus | Hold → Buy |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-10-20 | Eingeleitet | ROTH MKM | Neutral |
| 2023-08-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-05-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-03-29 | Eingeleitet | UBS | Sell |
| 2023-03-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-01-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-01-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Underweight |
| 2022-10-12 | Eingeleitet | Jefferies | Underperform |
| 2022-05-27 | Herabstufung | Needham | Buy → Hold |
| 2022-04-13 | Herabstufung | Truist | Buy → Hold |
| 2022-04-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Underperform |
| 2022-03-02 | Herabstufung | Loop Capital | Buy → Hold |
| 2022-02-08 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-02-08 | Bestätigt | Citigroup | Buy |
| 2022-02-08 | Bestätigt | Deutsche Bank | Hold |
| 2022-02-08 | Bestätigt | JMP Securities | Mkt Outperform |
| 2022-02-08 | Bestätigt | JP Morgan | Neutral |
| 2022-02-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-08 | Bestätigt | Stifel | Buy |
| 2022-02-08 | Bestätigt | Truist | Buy |
| 2022-02-08 | Bestätigt | UBS | Neutral |
| 2022-02-08 | Bestätigt | Wells Fargo | Underweight |
| 2022-02-02 | Herabstufung | UBS | Buy → Neutral |
| 2022-01-19 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-10 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-12-09 | Herabstufung | Needham | Strong Buy → Buy |
| 2021-12-07 | Eingeleitet | Loop Capital | Buy |
| 2021-11-23 | Herabstufung | Argus | Buy → Hold |
| 2021-09-14 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-09 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-18 | Bestätigt | Needham | Strong Buy |
| 2020-10-20 | Eingeleitet | Northland Capital | Market Perform |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-08-05 | Bestätigt | Needham | Strong Buy |
| 2020-04-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-04-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-04-07 | Bestätigt | Needham | Strong Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2020-01-07 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2020-01-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2019-12-04 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-10-07 | Hochstufung | BTIG Research | Neutral → Buy |
| 2019-09-18 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-08-12 | Hochstufung | Argus | Hold → Buy |
| 2019-07-30 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-06-11 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2019-04-24 | Hochstufung | Needham | Buy → Strong Buy |
Alle ansehen
Zimmer Biomet Holdings Inc Aktie (ZBH) Neueste Nachrichten
Zimmer Biomet To Acquire Iovera Pain Therapy Business For $140M - InkFreeNews.com
Zimmer Biomet focuses on orthopedic growth as investors weigh long-term demand - AD HOC NEWS
Zimmer Biomet stock holds focus on execution - AD HOC NEWS
Evercore ISI Adjusts Price Target on Zimmer Biomet to $110 From $120 - Moomoo
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Zimmer Biomet stock holds steady on thin coverage. Focus stays on execution. - AD HOC NEWS
Zimmer Biomet acquires rights to medical device for $140 million - Inside INdiana Business
JP Morgan Downgrades Zimmer Biomet Holdings (ZBH) - MSN
Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis: Navigating the Potential 12.84% Upside in the Healthcare Sector - DirectorsTalk Interviews
Enterprise value to revenue forward of Zimmer Biomet Holdings, Inc. – NYSE:ZBH - TradingView
Zimmer Biomet (ZBH) Stock Looks Cheap On Earnings But Faces Growth Doubts - Sahm
Zimmer Biomet Holdings Inc (ZBH) Shares Surge 3.9% -- What GF Sc - GuruFocus
Zimmer Biomet (ZBH) director awarded 389 Phantom Stock Units in deferred pay plan - Stock Titan
[Form 4] ZIMMER BIOMET HOLDINGS, INC. Insider Trading Activity - Stock Titan
Form 4 Zimmer Biomet Holdings Inc For: 2 July By Investing.com - Investing.com India
Zimmer Biomet (ZBH) director granted 317.369 cash-settled phantom stock units - Stock Titan
Zimmer Biomet (ZBH) director awarded 317.369 phantom stock units in cash-settled plan - Stock Titan
Phantom stock grant increases Zimmer Biomet (NYSE: ZBH) director units - Stock Titan
Zimmer Biomet (NYSE: ZBH) director receives cash-settled phantom stock grant - Stock Titan
Zimmer Biomet (ZBH) director receives new phantom stock unit award - Stock Titan
Medical device maker Zimmer Biomet to hire 500 in 3 years for tech centre in India - marketscreener.com
Enterprise value to EBIT forward of Zimmer Biomet Holdings, Inc. – NYSE:ZBH - TradingView
Zimmer Biomet (ZBH) Is Buying Pacira’s Iovera Device And Expanding Into Spasticity - Yahoo Finance
Zimmer Biomet Holdings | SD: Specialized disclosure report - Moomoo
Zimmer Biomet Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
‘Cool move’ by Zimmer part of med-tech’s tuck-in deals trend - BioWorld News
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal - Yahoo Finance
Pacira BioSciences to divest its iovera° business to Zimmer Biomet - Medical Buyer
Zimmer Biomet to acquire iovera device from Pacira for $140m - Yahoo Finance
BTIG Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating - Moomoo
Persona IQ from Zimmer Biometsmart knee implant brings continuous data to US surgeons - AD HOC NEWS
A Look at Zimmer Biomet Holdings Inc (ZBH) After 5.6% Decline -- GF Value $126.11 vs Price $86.09 - GuruFocus
Zimmer Biomet Holdings, Inc.'s Stock Price Plummets to $86.09, Suffers a Sharp 5.64% Drop - Smartkarma
Zimmer Biomet Holdings Inc. stock underperforms Tuesday when compared to competitors - MSN
Zimmer Biomet Holdings, Inc. agreed to acquire iovera ° Business of Pacira BioSciences from Pacira BioSciences, Inc. for $140 million. - marketscreener.com
Why is Zimmer Biomet stock sliding today? By Investing.com - Investing.com Canada
What is behind Zimmer Biomet stock's recent drop in value today - Traders Union
Pacira BioSciences (PCRX) Sells iovera° Business to Zimmer Biome - GuruFocus
Pacira divests iovera device to Zimmer Biomet for up to $140m - Investing.com
Pacira BioSciences stock rises on Zimmer Biomet deal By Investing.com - Investing.com South Africa
Pacira BioSciences stock rises on Zimmer Biomet deal - Investing.com UK
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet - The Manila Times
Pacira BioSciences to Divest iovera° to Zimmer Biomet for Up to $140 Million - Quiver Quantitative
Pacira (NASDAQ: PCRX) divests iovera° business to Zimmer Biomet for up to $140M - Stock Titan
Pacira offloads iovera° for up to $140M, keeps spasticity program - Stock Titan
Zimmer Biomet secures $2.75 billion credit, shares under Wall Street scrutiny - AD HOC NEWS
Zimmer Biomet Holdings (ZBH) Secures New Credit Agreements to Bo - GuruFocus
The Persona Knee System from Zimmer Biomet Holdings Inc.modular design tailored to each joint - AD HOC NEWS
Is Zimmer Biomet stock underperforming the S&P 500? - MSN
Zimmer Biomet Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Zimmer Biomet Expands Liquidity With New Credit Facilities - TipRanks
Finanzdaten der Zimmer Biomet Holdings Inc-Aktie (ZBH)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.74%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):